Build status - In Progress

Four-Repeat Tauopathy Neuroimaging Initiative

Four-Repeat Tauopathy Neuroimaging Initiative
Recruiting
99 years or below
All
1 Location

Brief description of study

New treatments that target the protein tau are beginning to enter human clinical trials. While tau-related therapies hold great promise for AD, clinical trials focusing on pure tauopathies are appealing because these diseases do not exhibit concurrent amyloid pathology. Pure 4 microtubule binding repeat (4R) tauopathies (4RT) include corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and some variants of frontotemporal lobar degeneration. There are no approved or effective therapies for 4RT. We designed 4RTNI to develop biomarkers of disease progression in CBD and PSP; such biomarkers may facilitate clinical trials for 4RT tauopathies.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: ['Corticobasal Degeneration (CBD)', 'Corticobasal Syndrome (CBS)', 'Cortical-basal Ganglionic Degeneration (CBGD)', 'Progressive Supranuclear Palsy (PSP)', 'Nonfluent Variant Primary Progressive Aphasia (nfvPPA)', 'Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)']
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 826254

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center